Pages that link to "Q37129949"
Jump to navigation
Jump to search
The following pages link to Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines (Q37129949):
Displaying 50 items.
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy (Q24596055) (← links)
- Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma (Q24635643) (← links)
- Treatment of metastatic melanoma: an overview (Q24642384) (← links)
- Improving the clinical impact of biomaterials in cancer immunotherapy (Q26766267) (← links)
- Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition) (Q26770492) (← links)
- Adoptive T-cell therapy for cancer: The era of engineered T cells (Q26800611) (← links)
- Insights into cytokine-receptor interactions from cytokine engineering (Q26852703) (← links)
- Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma (Q33407216) (← links)
- Immunotherapy: Vaccine trials in melanoma -- time for reflection (Q33434380) (← links)
- Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer (Q33680566) (← links)
- Vaccines against human carcinomas: strategies to improve antitumor immune responses (Q33734281) (← links)
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells (Q33977597) (← links)
- Tumor-initiating cells are rare in many human tumors (Q34156000) (← links)
- Phase I clinical trial of the vaccination for the patients with metastatic melanoma using gp100-derived epitope peptide restricted to HLA-A*2402 (Q34173622) (← links)
- gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma (Q34188859) (← links)
- The role of interleukin-2 during homeostasis and activation of the immune system (Q34255232) (← links)
- CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma (Q34299986) (← links)
- Therapeutic cancer vaccines: are we there yet? (Q34786691) (← links)
- Recent advances in cancer vaccines: an overview (Q34882348) (← links)
- Surgical management of melanoma brain metastases in patients treated with immunotherapy. (Q34954990) (← links)
- The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research (Q35000726) (← links)
- Differential expression of proteins in naïve and IL-2 stimulated primary human NK cells identified by global proteomic analysis (Q35077925) (← links)
- Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma. (Q35166973) (← links)
- Targeting the immunoregulator SRA/CD204 potentiates specific dendritic cell vaccine-induced T-cell response and antitumor immunity (Q35543558) (← links)
- Single-Cell Characterization of in vitro Migration and Interaction Dynamics of T Cells Expanded with IL-2 and IL-7. (Q35545785) (← links)
- Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus (Q35575688) (← links)
- Novel dendritic cell-based vaccination in late stage melanoma (Q35886439) (← links)
- Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination (Q35886450) (← links)
- Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma (Q36027584) (← links)
- Trial Watch: Adoptive cell transfer immunotherapy (Q36057432) (← links)
- Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. (Q36213487) (← links)
- Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion (Q36215613) (← links)
- Immunotherapy for melanoma: current status and perspectives (Q36453216) (← links)
- T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein (Q36552580) (← links)
- Oligodeoxynucleotides expressing polyguanosine motifs promote antitumor activity through the upregulation of IL-2. (Q36586115) (← links)
- Immune correlates of melanoma survival in adoptive cell therapy (Q36694896) (← links)
- PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells (Q36890941) (← links)
- Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape (Q37066106) (← links)
- Role of IL-2 in cancer immunotherapy (Q37079072) (← links)
- Safety and immunologic effects of IL-15 administration in nonhuman primates (Q37352474) (← links)
- Myeloid-derived suppressor cells: a novel therapeutic target (Q37393000) (← links)
- Metastatic melanoma - a review of current and future drugs (Q37450733) (← links)
- Functions of γC cytokines in immune homeostasis: current and potential clinical applications (Q37475949) (← links)
- Novel therapeutics for the treatment of metastatic melanoma (Q37486788) (← links)
- Exploiting the curative potential of adoptive T-cell therapy for cancer (Q37576033) (← links)
- Betting on immunotherapy for melanoma (Q37579301) (← links)
- Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients. (Q37650720) (← links)
- Influence of human immune cells on cancer: studies at the University of Colorado (Q37698684) (← links)
- Thoracic metastasectomy for adoptive immunotherapy of melanoma: a single-institution experience (Q37768258) (← links)
- Ipilimumab: A Novel Treatment for Metastatic Melanoma (Q37866936) (← links)